ICAD Expands Access To The Xoft System For Treating Non-Melanoma Skin Cancer To Dermatology Centers Via A Strategic Alliance With DermEbx

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced a strategic alliance with DermEbx™ to offer the Xoft ® Axxent ® Electronic Brachytherapy System ® to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of dermatology centers. DermEbx currently services 14 locations in Arizona, California and Nevada with Xoft System units placed in all locations.

“We are pleased to provide patients diagnosed with non-melanoma skin cancer this innovative and effective treatment option that is administered in their dermatologist’s office under the supervision of a radiation oncologist,” said Ken Ferry, iCAD’s CEO. “Electronic brachytherapy is a proven, non-invasive alternative to surgery, and this strategic alliance will allow us to expand the number of systems we have in place to treat more patients at centers managed by DermEbx. This agreement provides patients with a proven, convenient treatment alternative in a familiar care environment.”

“We are excited to bring the Xoft System to our managed centers as part of this strategic alliance,” said Kamal Gogineni, President of DermEbx. “The collaboration between DermEbx, dermatologists and its affiliated radiation oncologists will help create a comprehensive solution for this advanced technology in treating skin cancer patients.”

“DermEbx integrates the mobile Xoft System into its dermatology centers by allowing treatment to occur in the facility where the diagnosis is made, potentially eliminating the need to visit multiple service providers at different locations,” said David Berman, M.D., Medical Director, Berman Gladstone Skin Institute. “The mobility of the Xoft System enables a radiation oncologist to treat more patients at multiple dermatology centers.”

About Non-Melanoma Skin Cancer

NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is not only the most common type of skin cancer, it is the most common type of cancer in humans. These cancers commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips and backs of the hands. NMSC affects approximately 2.2 million Americans each year.

If you liked this article you might like

A Portfolio of Fixed Income, Pass Throughs and Small Caps

4 Stocks Under $10 to Trade for Breakouts

5 Breakout Stocks Under $10 Set to Soar

3 Stocks Under $10 Making Big Moves

How to Trade iCAD